Pharmacies in NSW and VIC are among the most tightly regulated businesses in Australia — and that regulation is precisely what makes them valuable. Licensing restrictions, PBS revenue, and location controls create a barrier to entry that buyers pay a significant premium for. The multiple range is 4.0× to 6.0× EBITDA, making pharmacies one of the highest-multiple sectors in the Australian small business market.
What the market is paying
| Business type | Typical multiple | Key driver |
|---|---|---|
| Small community pharmacy, declining scripts, ageing location | 3.5–4.0× EBITDA | Regulatory protection but limited growth |
| Established community pharmacy, stable PBS revenue, good location | 4.0–4.5× EBITDA | Recurring PBS revenue + community position |
| High-volume pharmacy, strong front-of-shop, compounding capability | 4.5–5.5× EBITDA | Revenue diversification + specialist capability |
| Medical centre co-location, high script volume, long lease | 5.5–6.5× EBITDA | Captive patient flow + premium location |
Why pharmacies command premium multiples
The Pharmacy Location Rules in NSW and VIC restrict where new pharmacies can open — you cannot simply open a pharmacy next to an existing one. This regulatory protection means that an established pharmacy has a defensible market position that a competitor cannot easily replicate. Buyers pay for that protection.
PBS (Pharmaceutical Benefits Scheme) revenue is recurring, government-backed, and largely independent of economic cycles. People need their medications regardless of what the economy is doing. That predictability is worth a premium multiple.
The pharmacist ownership requirement
In NSW and VIC, a pharmacy must be owned by a registered pharmacist or a company in which a pharmacist holds a controlling interest. This restricts the buyer pool to pharmacists and pharmacy groups — but it also means that buyers are typically well-capitalised and understand the business they are buying.
Script volume: the primary metric
Script volume — the number of PBS prescriptions dispensed per month — is the primary metric in a pharmacy valuation. Buyers will want to see script volume data for at least three years, broken down by category. A pharmacy with growing script volume in high-value categories (diabetes, cardiovascular, oncology) is more attractive than one with declining volume in commodity categories.
Front-of-shop: the margin opportunity
Front-of-shop sales — vitamins, cosmetics, personal care, OTC medications — generate significantly higher margins than PBS dispensing. Pharmacies with a strong front-of-shop operation and trained retail staff are more attractive to buyers than those that are purely dispensing-focused. The front-of-shop revenue also provides a buffer against PBS pricing changes.
NSW and VIC: where the deals happen
The majority of pharmacy transactions in Australia occur in NSW and VIC, driven by the density of population and the concentration of medical centres and hospitals. Buyers include individual pharmacists, pharmacy groups (Chemist Warehouse, Terry White, Priceline), and private equity-backed pharmacy consolidators.
